News Alexion lambasts NICE over rare disease ruling Watchdog accused of ignoring stakeholder consensus and call for negotiations
News Rare disease drug Strensiq too expensive, says NICE Alexion's new rare disease treatment Strensiq has been rejected by England's health watchdog NICE in draft guidance.
News JPM: AbbVie pays $650m upfront for RemeGen cancer drug AbbVie joins the ranks of companies developing cancer drugs that target both PD-1 and VEGF, via a $5.6bn licensing deal with China's RemeGen.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
